Excessive Daytime Somnolence: Clinical Trials

2 trials for Excessive Daytime Somnolence, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 32Completed 2
Phase 21Completed 1

Follow Excessive Daytime Somnolence: new trials by email Literature Review of Excessive Daytime Somnolence trials Research Report on Excessive Daytime Somnolence

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Open Label Study of FT218 in Subjects With Narcolepsy
FT218 - Narcolepsy, Cataplexy
Phase 3CompletedAvadel1842020-06-122025-10-02
Caffeine for Excessive Daytime Somnolence in Parkinson's Disease
Caffeine 100-200 mg BID, placebo - Parkinson's Disease, Excessive Daytime Somnolence
Phase 2 / Phase 3CompletedRon Postuma582007-04-012015-04-16

Narrower conditions

Disorders of Excessive Somnolence (2)  ·  Cataplexy (1)  ·  Narcolepsy (1)  ·  Parasomnias (1)  ·  Parkinson Disease (1)  ·  Sleep Wake Disorders (1)

Broader conditions

Dyssomnias (2)  ·  Mental Disorders (2)  ·  Nervous System Diseases (2)  ·  Sleep Disorders, Intrinsic (2)  ·  Basal Ganglia Diseases (1)  ·  Brain Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Movement Disorders (1)  ·  Neurodegenerative Diseases (1)  ·  Neurologic Manifestations (1)  ·  Parkinsonian Disorders (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Signs and Symptoms (1)  ·  Sleep Wake Disorders (1)  ·  Synucleinopathies (1)

Interventions

BID protein, human (1)  ·  Caffeine (1)

Sponsors

Avadel (1)  ·  Ron Postuma (1)

Countries

Canada (2)  ·  United States (1)

Top investigators

Ron Postuma, MD, MSc (1)

Results publications

PMID 39263597, PMID 42163487